Campbell & CO Investment Adviser LLC cut its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 10.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,316 shares of the company’s stock after selling 530 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Catalent were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently made changes to their positions in CTLT. Public Employees Retirement Association of Colorado boosted its stake in shares of Catalent by 29.2% during the 1st quarter. Public Employees Retirement Association of Colorado now owns 20,826 shares of the company’s stock worth $1,082,000 after acquiring an additional 4,707 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Catalent by 11.2% in the first quarter. Victory Capital Management Inc. now owns 34,091 shares of the company’s stock valued at $1,771,000 after buying an additional 3,429 shares in the last quarter. US Bancorp DE raised its stake in shares of Catalent by 28.9% during the 1st quarter. US Bancorp DE now owns 3,746 shares of the company’s stock worth $195,000 after buying an additional 839 shares during the period. MML Investors Services LLC raised its stake in shares of Catalent by 24.1% during the 1st quarter. MML Investors Services LLC now owns 6,137 shares of the company’s stock worth $319,000 after buying an additional 1,191 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of Catalent by 3.0% during the 1st quarter. Alliancebernstein L.P. now owns 280,814 shares of the company’s stock valued at $14,588,000 after buying an additional 8,200 shares in the last quarter.
Several equities analysts have issued reports on the stock. Morgan Stanley increased their price objective on shares of Catalent from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Royal Bank of Canada raised their price target on shares of Catalent from $94.00 to $98.00 in a research note on Tuesday, September 1st. Jefferies Financial Group reiterated a “buy” rating and set a $105.00 price objective on shares of Catalent in a research note on Tuesday, August 11th. Argus raised their target price on Catalent from $100.00 to $110.00 in a research report on Thursday, September 24th. Finally, Robert W. Baird boosted their price target on Catalent from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 1st. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Catalent presently has a consensus rating of “Buy” and a consensus target price of $96.78.
In other news, Director Gregory T. Lucier sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $90.09, for a total transaction of $2,162,160.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Grippo sold 1,680 shares of Catalent stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $94.99, for a total transaction of $159,583.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 233,433 shares of company stock worth $20,304,879. Corporate insiders own 1.00% of the company’s stock.
Shares of Catalent stock opened at $92.40 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 2.57 and a quick ratio of 2.20. The stock’s 50 day simple moving average is $86.75 and its 200-day simple moving average is $76.80. The stock has a market cap of $15.20 billion, a P/E ratio of 83.24, a P/E/G ratio of 2.64 and a beta of 1.58. Catalent, Inc. has a 1-year low of $31.04 and a 1-year high of $96.38.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, August 31st. The company reported $0.90 EPS for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.11. The firm had revenue of $947.60 million for the quarter, compared to the consensus estimate of $943.62 million. Catalent had a return on equity of 14.88% and a net margin of 7.13%. The firm’s revenue was up 30.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 earnings per share. As a group, research analysts expect that Catalent, Inc. will post 2.19 EPS for the current fiscal year.
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
See Also: Channel Trading
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.